Reimbursement codes obtained for doctor´s time during EVLP procedure
As of January 1, 2018, hospitals in the US will be able to use three CPT codes to obtain reimbursement for doctors’ time spent using the XPS for an EVLP (Ex Vivo Lung Perfusion) procedure. The new codes will also simplify the reimbursement process for the hospitals.
The XVIVO Perfusion US team with the help from Professor Ed Cantu (with the University of Pennsylvania) have worked for 18 months to secure CPT procedural codes for the XPS EVLP process. The first code is related to preparation of marginal donor lungs, the second code is related to the EVLP on an organ perfusion system of a marginal lung, and the third code is related to any additional hour(s) needed for an EVLP. The three codes together will simplify the process for reimbursement by the surgical team.
A CPT (Current Procedural Terminology) code is a direct mechanism for a hospital and surgical team to bill for a specific procedure. Therefore, with the new CPT codes, a barrier to use the XPS has been overcome. Thus, more clinicians will be able to bill for their efforts.
“We are pleased that 18 months of challenging work paid off in the three new CPT codes that will simplify for the US hospitals to get reimbursement as well as give the hospital the ability to get reimbursed for all the work the surgical team puts into an EVLP. The company believes that this will increase utilization of XVIVO Perfusion’s EVLP technology and products since a barrier is removed,” says XVIVO Perfusion’s CEO Magnus Nilsson.
November 7, 2017
Gothenburg
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 725 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on November 7, 2017.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
Tags: